#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4058	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2257	527.8	0	.	n	.	0	C451T	SNP	451	451	C	826	826	T	597	T,C	514,3	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4058	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2257	527.8	0	.	n	.	0	C1450T	SNP	1450	1450	C	1825	1825	T	595	T,G	551,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	4058	16S	1529	1529	99.87	16S.l15.c17.ctg.1	2257	527.8	1	SNP	n	C1184T	0	.	.	1184	1184	C	1559	1559	C	588	C	506	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6516	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3921	498.7	0	.	n	.	0	C331T	SNP	331	331	C	819	819	T	585	T,G	507,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6516	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3921	498.7	0	.	n	.	0	T695C	SNP	695	695	T	1183	1183	C	472	C	409	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6516	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3921	498.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2459	2459	C	624	C	552	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6516	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3921	498.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2533	2533	A	638	A,C,G	547,2,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6516	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3921	498.7	1	SNP	n	C2597T	0	.	.	2597	2597	C	3085	3085	C	598	C,A	513,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	27	578	folP	852	852	100.0	folP.l15.c4.ctg.1	1847	93.8	1	SNP	p	R228S	0	.	.	682	684	CGC	1195	1197	CGC	133;133;133	C;G;C	116;117;118	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1072	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3761	85.6	0	.	p	.	0	V19I	NONSYN	55	57	GTC	540	542	ATC	94;94;95	A;T;C	79;79;78	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1072	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3761	85.6	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1233	1235	ATA	79;79;79	A;T;A	72;71;73	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1072	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3761	85.6	1	SNP	p	S91F	0	.	.	271	273	TCC	756	758	TCC	97;97;97	T;C;C	91;90;89	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1072	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3761	85.6	1	SNP	p	D95N	0	.	.	283	285	GAC	768	770	GAC	97;97;97	G;A;C	90;90;91	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	1072	gyrA	2751	2751	99.75	gyrA.l6.c4.ctg.1	3761	85.6	1	SNP	p	D95G	0	.	.	283	285	GAC	768	770	GAC	97;97;97	G;A;C	90;90;91	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	506	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1488	101.1	0	.	p	.	0	D79N	NONSYN	235	237	GAT	670	672	AAT	152;151;150	A;A;T	126;125;127	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	506	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1488	101.1	1	SNP	p	G45D	0	.	.	133	135	GGC	568	570	GGC	127;128;128	G;G;C	109;113;111	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	326	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1263	77.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1614	1616	ATC	137;137;137	A;T,A;C	120;118,1;121	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1725	1727	GCC	134;134;134	G;C;C	116;116;115	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1767	1769	GCA	132;132;133	G;C;A	116;113;116	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	0	.	p	.	0	I596V	NONSYN	1786	1788	ATT	2250	2252	GTT	111;111;111	G;T;T	99;97;101	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	1	SNP	p	D86N	0	.	.	256	258	GAC	720	722	GAC	167;168;168	G;A;C	140;141;144	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	1	SNP	p	S87I	0	.	.	259	261	AGT	723	725	AGT	167;168;168	A;G;T	142;142;138	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	1	SNP	p	S87W	0	.	.	259	261	AGT	723	725	AGT	167;168;168	A;G;T	142;142;138	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	1	SNP	p	S87R	0	.	.	259	261	AGT	723	725	AGT	167;168;168	A;G;T	142;142;138	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	1162	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3285	106.1	1	SNP	p	S88P	0	.	.	262	264	TCC	726	728	TCC	169;171;169	T;C;C	140;141;143	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1044	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3030	103.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1745	1747	GGC	133;133;134	G,C;G;C	119,1;117;119	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1426	1428	GCA	166;167;165	G;C;A	140;138;141	penA.0.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1429	1431	ATC	165;165;167	A,G;T;C,A	137,1;143;139,1	penA.0.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1441	1443	GTG	163;164;163	G;T;G,T	140;137;139,1	penA.0.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1441	1443	GTG	163;164;163	G;T;G,T	140;137;139,1	penA.0.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1942	1944	ACC	140;140;140	A;C;C	121;118;120	penA.0.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1996	1998	GCG	128;126;125	G,T;C,G;G	111,1;105,1;104	penA.0.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1996	1998	GCG	128;126;125	G,T;C,G;G	111,1;105,1;104	penA.0.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	G542S	0	.	.	1624	1626	GGC	2119	2121	GGC	132;131;131	G;G;C	115;117;115	penA.0.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2128	2130	GGC	128;127;128	G;G;C	114;111;112	penA.0.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.0.001	penA.0.001	1	1	27	1126	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2758	122.2	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2146	2148	CCG	128;127;126	C,G;C;G	110,1;114;108	penA.0.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1406	ponA	2397	2397	99.87	ponA.l6.c30.ctg.1	3349	125.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	494	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2020	73.1	0	.	p	.	0	S22G	NONSYN	64	66	AGC	423	425	GGC	61;62;64	G;G,C;C	51;53,2;56	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	494	porA	1146	1146	99.74	porA.l15.c4.ctg.1	2020	73.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	605	605	C	75	C	65	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	A29V	NONSYN	85	87	GCC	429	431	GTC	156;155;154	G;T;C	132;131;130	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	T50A	NONSYN	148	150	ACT	492	494	GCT	157;157;156	G;C;T	136;138;138	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	K88L	NONSYN	262	264	AAA	606	608	CTC	167;167;166	C;T;C	145;144;143	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	S93N	NONSYN	277	279	AGC	621	623	AAC	170;170;171	A;A;C	147;146;146	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	N114S	NONSYN	340	342	AAC	684	686	AGC	158;158;159	A;G;C	145;144;144	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	I115V	NONSYN	343	345	ATC	687	689	GTC	158;158;159	G;T;C,T	145;140;144,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	D120G	NONSYN	358	360	GAC	702	704	GGC	159;159;163	G;G;C	143;143;145	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	S129N	NONSYN	385	387	AGC	729	731	AAC	162;164;164	A;A;C	142;146;145	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	Y201F	NONSYN	601	603	TAC	945	947	TTC	190;191;191	T;T;C	163;163;163	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	539	848	porB1a	984	984	98.48	porB1a.l15.c17.ctg.1	1666	149.7	0	.	p	.	0	S236R	NONSYN	706	708	AGC	1050	1052	CGC	199;198;197	C;G,C;C	171;172,1;173	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2570	rpoB	4179	4179	99.93	rpoB.l15.c4.ctg.1	5100	151.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2047	2049	CAT	146;145;145	C;A;T	133;134;132	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	376	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1248	90.3	1	SNP	p	V57M	1	.	.	169	171	ATG	641	643	ATG	163;162;162	A;T;G	139;138;136	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
